We are welcoming promising results from the latest study into a vaccine to protect against meningococcal group B disease (MenB), the most common cause of bacterial meningitis in the UK.

The study, published in the medical journal The Lancet today, showed positive results in the vaccine’s protection of adolescents, one of the at risk groups for the disease. The 4CMenB vaccine also had positive results from studies conducted last summer into its protection of infants and toddlers, who account for nearly half of all meningitis cases. Together, these studies provide promising indications for the effectiveness of the vaccine, and we are delighted to learn that the Joint Committee on Vaccine and Immunisation (JCVI) will be considering the vaccine for introduction in the UK.

Sue Davie, our Chief Executive, says; “Meningitis B is a terrifying disease, striking with little warning and devastating lives in a matter of hours. Around 1,200 people every year in the UK fall victim to this strain of meningitis. Up to 10% of all cases result in death and 15% of those who survive will be left with severe after-effects, whilst many more will be left with hidden, but life-changing, after-effects. This is a disease that tears lives apart and leaves a lasting legacy, which is why having a safe and effective vaccine to help protect against it is so important.

“However, while we celebrate every step towards a possible new vaccine that can help protect more lives, it is essential that people do not think the problem is sorted – this will put lives at risk. Unfortunately there will always be meningitis in some form, even after the introduction of a MenB vaccine, so vigilance to the signs and symptoms is essential. We are urging the public and health professionals to remember that meningitis still poses a threat to people, young and old, across the UK and must remain high on people’s agendas.”

Findings from a unique scientific study* that we commissioned into the impact of MenB in the UK showed that a significant number of children who survive are living with a huge burden following the disease. As well as the more obvious after-effects, such as brain damage, deafness and limb loss (where  septicaemia has occurred), they often suffer from hidden problems such as reduced IQ, memory issues and  mental health problems and are significantly more likely to have special educational needs. We are using these findings to support the introduction of a vaccine to protect against MenB and have taken the results to the Government with a campaign to get better support for its victims, particularly children, who continue to struggle with the impact. More information on the campaign can be found at www.MeningitisChangesFutures.co.uk

We are dedicated to providing support for life to anyone living with the impact of meningitis through are free, tailored support across the UK. We help 20,000 people every year and are committed to raising lifesaving awareness of the disease and its symptoms. You can call our helpline, 0800 028 18 28, for more information.

*The Meningitis Trust’s commissioned MOSAIC (Meningococcal Outcomes Study in Adolescents and in Children) research into the physical, psychological, social and economic burden of meningococcal group B.